ArticleZeitschrift fur Geburtshilfe und Neonatologie2026
Differential Analysis of Neonatal Adverse Drug Events from Intrauterine and Extrauterine Exposure: Insights into Administration Routes Using the FAERS Database.
Article in Zeitschrift fur Geburtshilfe und Neonatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically characterize the features and drug distribution of neonatal adverse drug reactions using data from the FAERS, with a focus on exposure-specific patterns and stratified analyses by sex and clinical outcomes. Methods: Reports submitted to FAERS from the first quarter of 2004 to the fourth quarter of 2024 were utilized. Patients experienced the ADR at an age of no more than 28 days. Four quantitative disproportionality analysis methods, including ROR, PRR, BCPNN, and MGPS, were used to detect signals of adverse drug events. Results: A total of 15,456 neonatal cases exposed to the target drugs were included, yielding 60,611 adverse event reports, 95.45% of which were classified as serious. The median time to onset of ADRs was 264 days for intrauterine drug exposure, compared to 1-3 days for extrauterine exposure. The most affected SOCs were injury and procedural complications (19.53%), congenital disorders (15.96%), and pregnancy/perinatal conditions (8.65%). Transplacental exposure accounted for the highest proportion (52.47%), followed by intravenous (9.34%), oral (6.77%), breastfeeding (1.80%), intramuscular (1.48%), and inhalation (1.29%). The top maternal exposure drugs included venlafaxine, sertraline, quetiapine, lamotrigine, and levetiracetam. For intravenous use, levetiracetam, zidovudine, indomethacin, ibuprofen, and vancomycin were most common. Female neonates had higher risks of microcephaly, ventricular septal defect, and growth restriction, while male neonates were more prone to hypospadias, cryptorchidism, and agitation. Serious AEs were mainly linked to maternal drug exposure during pregnancy. Conclusion: These results showed that the use of antidepressants, antiepileptics, and antivirals during pregnancy represents a significant risk factor for neonatal adverse reactions, particularly congenital malformations. Consequently, it is imperative to implement precise prevention strategies tailored to specific exposure stages and to advocate for the establishment of an international pharmacovigilance network for neonates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.